Anumigilimab
As of the edition of 20 October 2026, Anumigilimab is an antibody: in active development; acts on CSF3R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 5, 1 stopped early
- Disease areas
- Infections; Blood and lymph; Inherited and neonatal; Lungs and airways; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CSF3R | Granulocyte colony-stimulating factor receptor | Q99062 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 2 | 0 | 1 | 1 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| CSL Behring | Lead sponsor of trials | 2019 to now |